Condition: Hodgkin Lymphoma · Sponsor: St. Petersburg State Pavlov Medical University
Patients in this prospective multicenter phase II study will be randomized between two first-line therapy strategies for advanced stages of cHL. In the Nivo-AVD cohort, patients will receive 2 cycles of nivolumab monotherapy followed by a switch to Nivo-AVD combination therapy (total of 6 cycles); in the Standard cohort, patients will receive therapy according to current clinical guidelines in Russian Federation for first-line therapy of cHL, which include starting first-line therapy with 2 cycles of BEACOPP-like regimens and, after assessing response after 2 courses, switching to A(B)VD or continuing with BEACOPP-like regimens
This description comes directly from the study's public registry record.
Liudmila Fedorova, MD, PhD · +78123386265 · md.FedorovaL@gmail.com
Polina Kotseliabina, MD · +78123386265 · polina.kotselyabina.med@gmail.com
Always discuss trial participation with your own doctor first.
| A.N.Bakulev Center for cardiovascular surgery of the Russian Ministry of Health | Moscow, Russia | Recruiting |
| National Medical and Surgical Center named after N.I. Pirogov | Moscow, Russia | Recruiting |
| St. Petersburg State Pavlov Medical University | Saint Petersburg, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07234487